18920

I was disappointed in “Blood relatives.” It ignored the pioneering work by people at the company Somatogen, now known as Baxter Hemoglobin Therapeutics. They first published work on a recombinant hemoglobin for use as a blood substitute in Nature in 1990. Later, they demonstrated definitively that many of the problems associated with blood substitutes were caused by nitric oxide scavenging and designed a recombinant hemoglobin that significantly decreased that activity. Bruce A. Kerwin
Thousand Oaks, Calif.